Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsayil LTE long-term spesolimab extension in hidradenitis suppurativa
jRCT2031240075Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Started Jul 2024; status: completed.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on jRCT2031240075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240075.